University of Wollongong

Research Online
University of Wollongong Thesis Collection

University of Wollongong Thesis Collections

2014

Eye plaque dosimetry verification using novel solid
state devices
Talia Jarema
University of Wollongong

Recommended Citation
Jarema, Talia, Eye plaque dosimetry verification using novel solid state devices, Master of Science - Research thesis, Faculty of
Engineering, University of Wollongong, 2014. http://ro.uow.edu.au/theses/4060

Research Online is the open access institutional repository for the
University of Wollongong. For further information contact the UOW
Library: research-pubs@uow.edu.au

Eye Plaque Dosimetry Verification using Novel Solid State Devices

By
Talia Jarema

Submitted in partial fulfilment of the requirements for the award of the degree of
M Science (Research)

From

University of Wollongong
Faculty of Engineering

May 2014

CERTIFICATION

I, Talia K. Jarema, declare that this thesis, submitted in partial fulfilment of the
requirements for the award of Master of Science (Research), in the Department of
Medical Radiation Physics, University of Wollongong, is wholly my own work unless
otherwise referenced or acknowledged. The document has not been submitted for
qualifications at any other academic institution.

Talia Kate Jarema

i

ACKNOWLEDGEMENTS

I’d like to express my appreciation to all of my supervisors- Dr. Dean Cutajar,
Professor Peter Metcalfe and Professor Anatoly Rosenfeld for their guidance and
help throughout this research. I’d especially like to thank Dean for his inspiration
and guidance throughout the writing of this thesis. Thanks also to Michael Weaver,
Dr Michael Lerch and Dr Marco Petasecca for contributing to and aiding the research
which follows.
On a more personal note, I want to thank my parents, housemates and friends for
being supportive and giving me a life beyond my studies. Above all others, I’d like
to thank Jack who has been more supportive than I could have hoped for while
writing this thesis. He has helped me keep calm at every turn, and for that I am
extremely grateful.

ii

ABSTRACT
Eye plaque brachytherapy is a radiation treatment modality, currently used to treat
ocular malignancies. To date, there are no dosimeters used clinically which are
capable of determining the dose rate in real time from brachytherapy eye plaques.
This research aims to progress the implementation of a new dosimetry technique,
spectroscopic dosimetry, clinically, and involved the development and verification
of a dose map for eye plaque brachytherapy through three experimental dosimetric
methods as well as theoretical calculations.
MOSFET based surface dosimeters were used to determine the surface and scleral
dose in close proximity to the eye plaque. These were calibrated using TG-43
specifications, and gained results within the expected range. To determine the dose
rate at depths from the plaque, Gafchromic film was used. Using the TG-43
guidelines to calibrate the film, dose rates were determined and used for comparison
with the spectroscopic dosimeter. The film results were found to agree with the TG43 calculated doses. As TG-43 is held as the gold standard for brachytherapy
dosimetry, it is used as the benchmark for all other dosimeters in this research.
A silicon detector based real time dosimeter was developed specifically for quality
assurance measurements in eye plaque brachytherapy, using a method of
spectroscopic dosimetry. A comparison was made between TG-43 predicted results
and the spectroscopic detector. These results were accurate and in close agreement,
showing that the spectroscopic probe is an accurate method of dosimetry for ROPES
eye plaques.
With the MOSFET based dosimeters obtaining accurate scleral dose measurements
and the spectroscopic detector obtaining fast doses at depths, it can be stated that
solid state devices may be used to obtain a complete dose map during eye plaque
brachytherapy.

iii

TABLE OF CONTENTS
CERTIFICATION ....................................................................................................................................... i
ACKNOWLEDGEMENTS.......................................................................................................................... ii
ABSTRACT.............................................................................................................................................. iii
LIST OF FIGURES .................................................................................................................................... vi
LIST OF TABLES...................................................................................................................................... ix
1.

INTRODUCTION............................................................................................................................... 1

2.

LITERATURE REVIEW ...................................................................................................................... 3
2.1.

EYE PLAQUE BRACHYTHERAPY ............................................................................................ 3

2.1.1.
2.2.

EYE PLAQUES ......................................................................................................................... 5

2.2.1.

SOURCES ......................................................................................................................... 6

2.2.2.

THE TG-43 FORMALISM ............................................................................................... 10

2.3.

DOSIMETRY FOR EYE PLAQUES ........................................................................................... 13

2.3.1.

TLDS ............................................................................................................................. 13

2.3.2.

GAFCHROMIC FILM ...................................................................................................... 16

2.3.3.

CALIBRATION OF GAFCHROMIC FILM ........................................................................ 18

2.4.

SCLERAL DOSE ..................................................................................................................... 19

2.5.

MOSFET DOSIMETRY .......................................................................................................... 21

2.5.1.

MEASUREMENT OF RADIATION FIELDS USING MOSFETS ........................................ 21

2.5.2.

CURRENT USES OF MOSFETS ..................................................................................... 23

2.5.3.

ADVANTAGES OF THE MOSFET ................................................................................. 24

2.5.4.

DISADVANTAGES ......................................................................................................... 25

2.6.

MOSKIN .................................................................................................................................. 26

2.7.

SPECTROSCOPIC DOSIMETRY ............................................................................................... 27

2.7.1.
3.

4.

IODINE-125 ................................................................................................................... 27

CALIBRATION OF MOSFET DETECTOR ....................................................................................... 29
3.1.

METHOD OF DETERMINING THE CALIBRATION FACTOR .................................................. 29

3.2.

RESULTS ................................................................................................................................ 30

3.3.

DISCUSSION OF PRACTICAL IMPLICATIONS ....................................................................... 33

SCLERAL DOSE MAPPING ............................................................................................................ 34
4.1.

METHODS ............................................................................................................................. 34

4.1.1.

iv

OCULAR MALIGNANCIES .............................................................................................. 5

MAXIMUM SCLERAL DOSE RATES .............................................................................. 34

4.1.2.
4.2.

RESULTS ................................................................................................................................ 36

4.2.1.

MAXIMUM SCLERAL DOSE RATE ................................................................................ 36

4.2.2.

SURFACE DOSE UNDER PLAQUE ................................................................................. 40

4.3.

DISCUSSION .......................................................................................................................... 43

4.3.1.

MAX SCLERAL DOSE RATE .......................................................................................... 43

4.3.2.

SCLERAL MAP .............................................................................................................. 43

4.4.
5.

FUTURE RESEARCH .............................................................................................................. 44

DEPTH DOSE USING GAFCHROMIC FILM .................................................................................... 46
5.1.

METHODS ............................................................................................................................. 46

5.1.1.

6.

CALIBRATION ............................................................................................................... 47

5.2.

RESULTS ................................................................................................................................ 50

5.3.

DISCUSSION .......................................................................................................................... 56

SPECTROSCOPIC DOSIMETRY ....................................................................................................... 57
6.1.

METHODS ............................................................................................................................. 59

6.1.1.

SENSITIVE VOLUME ...................................................................................................... 59

6.1.2.

CALIBRATION ............................................................................................................... 61

6.1.3.

DOSE AT DEPTHS.......................................................................................................... 62

6.2.

RESULTS ................................................................................................................................ 64

6.2.1.
6.3.
7.

SURFACE DOSE UNDER PLAQUE ................................................................................. 35

DETECTOR FUNCTIONALITY ........................................................................................ 66

DISCUSSION .......................................................................................................................... 71

CONCLUSION ................................................................................................................................ 73

7.1. FUTURE APPLICATIONS ................................................................................................................ 75
8.

REFERENCES .................................................................................................................................. 77

9.

APPENDIX 1 ................................................................................................................................... 80

v

LIST OF FIGURES
FIGURE 2- SIZE COMPARISON OF BOTH THE SEED AND THE ACTIVE VOLUME OF A. THE
ISOAID ADVANTAGE I-125 AND B. THE ONCOSEED THINSEED 9011. ADAPTED FROM
[22] AND [23] ...................................................................................................................... 9
FIGURE 3 GEOMETRY FACTOR, ADAPTED FROM [19] ............................................................. 12
FIGURE 7 STRUCTURE OF THE HUMAN EYE [46] ..................................................................... 20
FIGURE 8- A SIMPLE MOSFET DESIGN [51]........................................................................... 22
FIGURE 9- THE OBSERVED SHIFT IN THRESHOLD VOLTAGE OF A MOSFET DETECTOR [51] .. 23
FIGURE 10- MOSFET WITH EPOXY BUBBLE, COMPARED WITH THE UNIFORM BUILD-UP
LAYER OF THE MOSKIN [54]. ........................................................................................... 26

FIGURE 11- I-125 SPECTRUM, FROM AN ONCURA 6711 SEED, SHOWING THE TWO MOST
PROMINENT PEAKS, MEASURED WITH A SILICON DETECTOR. COURTESY OF DEAN

CUTAJAR [50]. .................................................................................................................. 28
FIGURE 12 EXPERIMENTAL SETUP, WITH A SURROUNDING MEDIUM OF SOLID WATER,
EXTENDING A MINIMUM OF 4.5CM IN ALL OTHER DIRECTIONS FROM THE
BRACHYTHERAPY SEED, WITH ADDITIONAL PMMA USED FOR APPROPRIATE
BACKSCATTER ................................................................................................................... 30

FIGURE 13- THE RESPONSE OF A MOSFET TO A KNOWN RADIATION SOURCE OVER TIME.
THE ERROR IN READINGS WAS APPROXIMATELY 1%. ...................................................... 32
FIGURE 14- EYE PHANTOM...................................................................................................... 34
FIGURE 15- LABELLED MOSFET POSITIONS UNDER EYE PLAQUE. ....................................... 35
FIGURE 16- THE MOSKIN RESPONSE OVER TIME IN POSITION 1, WITH AN ERROR IN MOSKIN
READING OF 1%. ............................................................................................................... 38

FIGURE 17- DOSE VS. TIME FOR A FULLY LOADED ROPES PLAQUE IN POSITION 1, WITH
SEEDS OF ACTIVITY 0.282MCI, NORMALIZED TO 0.4MCI WITH AN EXPERIMENTAL ERROR
OF APPROXIMATELY 1%.................................................................................................... 39

FIGURE 18- DOSE RATE IN

VARIOUS SCLERAL POSITIONS NORMALISING THE SOURCE

ACTIVITY TO 0.4MCI, AS CALCULATED USING EQUATION 12. ERROR IS ESTIMATED FROM
ERROR ASSOCIATED WITH MOSKIN DETECTOR. .............................................................. 40

vi

FIGURE 19- DOSE RATE TO MOSKIN SITUATED UNDER PARTICULAR POSITIONS OF AN EYE
PLAQUE USING SOURCES SIMULATING AN ACTIVITY OF 0.4MCI (EQUATION 12). ERROR
DERIVED FROM POTENTIAL ERROR IN MEASUREMENT IN THE MOSKIN.......................... 41

FIGURE 21- SEGMENTED EYE PHANTOM ................................................................................ 46
FIGURE 22- FILM CALIBRATION CHART. ERROR IN NET OD DERIVED FROM THE STANDARD
DEVIATION OF THE MEASUREMENTS IN IMAGEJ .............................................................. 49

FIGURE 23- THE THREE COLOUR CHANNELS OF SLICE 6. THE MOST DISTINCT COLOUR
CHANGE CAN BE SEEN IN THE RED CHANNEL .................................................................. 49

FIGURE 24- 7 SHEETS OF FILM FROM EYE PHANTOM AFTER BEING LEFT FOR 72 HOURS WITH A
15MM ROPES EYE PLAQUE CONTAINING 10 SEEDS AT 0.215MCI .................................. 51
FIGURE 25- SEGMENTED EYE PHANTOM SHOWING LABELLED FILM POSITIONS ..................... 51
FIGURE 26- DEPTH DOSE OBTAINED USING FILM AND TG-43 CALCULATIONS, USING 10
SEEDS OF 0.215MCI IN A 15MM ROPES PLAQUE FOR 72 HOURS OF EXPOSURE .............. 53

FIGURE 27- 7 SHEETS OF FILM IRRADIATED FOR 72 HOURS WITH 7 I-125 BRACHYTHERAPY
SEEDS, PLACED IN THE OUTER HOLDER POSITIONS (4-10) OF THE 15MM ROPES PLAQUE,
USING SEEDS WITH AN ACTIVITY OF 0.195MCI ................................................................ 54

FIGURE 28- THE CENTRAL AND MAXIMUM DOSE FOUND USING 7 SEEDS OF ACTIVITY
0.195MCI IN A 15MM ROPES PLAQUE FOR 72 HOURS OF EXPOSURE, SHOWING THE
DIFFERENCE BETWEEN THE TWO IS GREATER CLOSER TO THE PLAQUE.

.......................... 55

FIGURE 29 PROFILE ACROSS THE CENTRE OF FILM FROM POSITION NUMBER 7, USING ONLY 7
SEEDS. ANALYSED BY INVERTING THE IMAGE, HIGHLIGHTING THE DIFFERENCE IN DOSE
ALONG THE CENTRAL AXIS ............................................................................................... 55

FIGURE 30- SPECTROSCOPIC DOSIMETER DEVELOPED AT THE CMRP WOLLONGONG. THE
TIP SEEN IN LATER FIGURES IS TO THE LEFT, WITH THE PREAMPLIFIER ON THE RIGHT. ... 57

FIGURE 31- RAW I-125 SPECTRUM OBSERVED BY THE SPECTROSCOPIC DOSIMETER. THE
SHARP PEAK AT 20 KEV SHOWS THE DISCRIMINATOR PULSE, BELOW WHICH, NO
INTEGRATION IS PERFORMED.

.......................................................................................... 58

FIGURE 32- X-RAY OF THE ORIGINAL SPECTROSCOPIC DOSIMETER DESIGN SHOWING THE TIP
OF THE DETECTOR AND SENSITIVE VOLUME, AS WELL AS THE CERAMIC HOLDER.

......... 60

FIGURE 33- X-RAY IMAGE OF THE MODIFIED SPECTROSCOPIC DETECTOR, SHOWING THE
SENSITIVE VOLUME MUCH CLOSER TO THE TIP (4MM). .................................................... 61

vii

FIGURE 34- EXPERIMENTAL SETUP OF SPECTROSCOPIC DETECTOR......................................... 63
FIGURE 35 PHOTOGRAPH OF THE SPECTROSCOPIC DOSIMETER APPARATUS.......................... 64
FIGURE 36- MEASURED DEPTH DOSE OF THE SPECTROSCOPIC DETECTOR. THE SOURCE
ACTIVITY WAS NORMALISED TO 0.4MCI (EQUATION 12), A 10 SECOND TIMER WAS USED,
AND 3 TO 4 OUTPUTS WERE AVERAGED TO OBTAIN THE DATA. THE RESULTS HAD AN
EXPERIMENTAL ERROR TO WITHIN 1% ............................................................................. 65

FIGURE 37 SPECTRA OBTAINED USING A SPECTROSCOPIC DOSIMETER AND FULLY LOADED I125 ROPES EYE PLAQUE WITH A TIP TO PLAQUE DISTANCE OF 1MM ............................. 67
FIGURE 38 SPECTRA OBTAINED USING A SPECTROSCOPIC DOSIMETER AND FULLY LOADED I125 ROPES EYE PLAQUE WITH A TIP TO PLAQUE DISTANCE OF 2MM ............................. 67
FIGURE 39 SPECTRA OBTAINED USING A SPECTROSCOPIC DOSIMETER AND FULLY LOADED I125 ROPES EYE PLAQUE WITH A TIP TO PLAQUE DISTANCE OF 3MM ............................. 68
FIGURE 40 SPECTRA OBTAINED USING A SPECTROSCOPIC DOSIMETER AND FULLY LOADED I125 ROPES EYE PLAQUE WITH A TIP TO PLAQUE DISTANCE OF 5MM ............................. 68
FIGURE 41 SPECTRA OBTAINED USING A SPECTROSCOPIC DOSIMETER AND FULLY LOADED I125 ROPES EYE PLAQUE WITH A TIP TO PLAQUE DISTANCE OF 10MM ........................... 69

viii

LIST OF TABLES
TABLE 1- BRACHYTHERAPY SOURCES AND SOME FACTORS THAT AFFECT TREATMENT.
ADAPTED FROM [11] .......................................................................................................... 7
TABLE 2 RADIAL DOSE FUNCTION VARIATION WITH RADIAL DISTANCE, ADAPTED FROM [26]
.......................................................................................................................................... 37
TABLE 3- RESULTS FROM FILM CALIBRATION .......................................................................... 48
TABLE 4- MAXIMUM DOSE RATE RESULTS FROM FILM IRRADIATED FOR 72 HOURS WITH 10
SEEDS OF ACTIVITY 0.215MCI IN A ROPES EYE PLAQUE. THE AVERAGE PIXEL VALUE
WAS FOUND USING A CIRCULAR ROI OF 50 PIXEL DIAMETER IN IMAGEJ........................ 52

TABLE 5- FWHM COMPARISON OF PEAKS OBTAINED AT VARYING DEPTHS USING AN I-125
SOURCE ............................................................................................................................. 70

TABLE 6- RATIO OF COUNTS OBTAINED IN EACH SPECTRA AND THE DOSE RATE AT SPECIFIED
DEPTH ............................................................................................................................... 71

ix

1. INTRODUCTION
The 2011 projections for the incidences of eye cancer in Australia are 326 new cases
nationwide each year in a population of 22,485,300 [1], [2]. These projections show an
overall increase in ocular malignancies of 37% over the next decade [3].
The treatment of ocular malignancies through the use of eye plaque brachytherapy
has been researched and developed since the therapy’s first success using radon
seeds in 1939 [4]. In the seven decades since this initial success, the development of
eye plaque brachytherapy has taken many leaps forward. Currently, there are many
treatment centres in Australia that offer eye plaque brachytherapy as a primary
treatment plan for patients suffering from various ocular malignancies.
In the past, the dosimetry of eye plaques has been conducted using TLD arrays, with
the addition of computer simulations [5]. However, as the eye is a relatively small
organ, a TLD array cannot give a high enough spatial resolution to ensure that the
small critical structures within the eye, such as the optic nerve or optic disc, will
remain safe throughout treatment. A new generation of dosimeters, however, have
the ability to obtain the spatial resolution required to ensure that no unnecessary
dose is absorbed by these structures.
Currently, there is no clinically implemented dosimetry method that allows for fast,
real time dose rate measurements for eye plaques. This research aims to further
develop and test such a dosimeter, progress the advancement of technologies, and
investigate whether they have the potential to be implemented in a clinical
environment.
There are two distinct goals to the research presented in this thesis. The first involves
using MOSFETs to map the dose received by the sclera during eye plaque
brachytherapy. MOSFETs lend themselves to measurements involving high spatial
resolution, and are ideal for surface measurements in steep dose gradient fields.
The second goal is to compare depth dose results using a spectroscopic dosimeter,
verifying the results against that of a current treatment planning system (based on
1

the TG43 formalism) and analytical results [5]. Spectroscopic dosimetry does not
have the same high spatial resolution provided by a MOSFET, but may provide
accurate, real time results.
The scleral doses were measured using MOSFETs, and determined analytically
using TG-43 formalism based calculations, whereas Gafchromic film and
spectroscopic dosimeters were used to determine dose at depths. These results, if
found to be reproducible and accurate, will contribute to the formulation of a quality
assurance system, whereby dosimetric measurements can be taken and planning
system results verified immediately before patient treatment.
The implications from both goals of this research in terms of clinical uses would be
especially useful as any unwanted dose to critical structures of the eye could be
observed beforehand and the treatment plan altered accordingly, potentially saving
the sight or eye itself for numerous patients undergoing eye plaque brachytherapy.
Improved dosimetry may progress the viability of the treatment at other centres
across the country.

The overall aims of this research are to:
i.

Develop a scleral dose map to provide information as to the areas of the sclera
that are at the greatest risk of necrosis or other adverse effects.

ii.

Develop a method by which eye plaque dosimetry can be performed quickly
and with ease, potentially before treatment begins.

iii.

Compare and ensure the feasibility of the dosimetry, by studying the results
obtained through MOSFET and spectroscopic dosimetry.

2

2. LITERATURE REVIEW
2.1. EYE PLAQUE BRACHYTHERAPY
Currently, one of the most popular sources used in eye plaque brachytherapy are
Iodine-125 (I-125) seeds [7]. These radioactive seeds are mounted in a holder called
an eye plaque, consisting of a plastic backing in which to mount the brachytherapy
seeds, as seen in Figure 1 with an outer metal casing.
The metal casing used in COMS (Collaborative Ocular Melanoma Study) eye
plaques is most often gold. However, the backing for ROPES (Radiation and
Oncology Physics and Engineering Services, Australia) eye plaques, is steel. The
backing has the purpose of preventing the radiation from the source penetrating
critical structures such as the brain which may be located behind the plaque.
The eye plaque used throughout this study was a ROPES plaque and therefore uses
a stainless steel backing. Although the ROPES plaque comes in various sizes, the
plaque used throughout this research is a 15mm plaque, which holds 10
brachytherapy seeds.
The plaque is surgically sewn onto the eye, behind the tumour. The plaque remains
in place for approximately 4 days, administering the radiation dose (Treatment time
can span anywhere from 3 to 7 days) [8].

3

Figure 1- ROPES eye plaque [9]

Until eye plaque brachytherapy was adopted, the most popular treatment for ocular
malignancies was enucleation, whereby the affected eye was removed [11].
Treatment by this method has changed however for two important reasons. The first,
is that studies have shown that there is a potential link between enucleation and the
incidence of secondary tumours occurring in the liver [7]. Despite the lack of
concrete evidence to support it, the current theory linking enucleation and
metastases suggests that the agitation of the tumour in the eye during its removal
may disturb the malignant cells it and cause them to spread. The second, is the
potential to preserve sight in the afflicted eye.
Although not available in Australia, proton therapy is also favoured over
enucleation in other parts of the world [12]. The advantage of the use of eye plaque
brachytherapy over proton therapy however, is that proton therapy is expensive due
to the equipment required [13].
In Australia, where proton therapy is unavailable, the major advantage of treatment
using brachytherapy in comparison to other treatment modalities such as
enucleation is the likelihood of patients retaining at least some vision in their
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affected eye. Brachytherapy, whilst having the potential to decrease a patient’s
vision (and an added, although minimised risk to the patient to lose vision in the eye
completely), still gives a greater chance to most patients of retaining vision than
enucleation. Despite the inherent risk to the patient’s vision, it is highly dependent
on tumour type and location, and is generally a heavily weighed factor in the
determination of the treatment modality.
The current dosimetry used for eye plaque brachytherapy is time consuming and
inadequate. As a result, the information gained in the dosimetry process is assumed
true, and there is no verification between the planning system and the experimental
data for every patient. If there was a method through which the loaded plaque
dosimetry could be verified to the planning system quickly and with ease, a loaded
eye plaque could have its dose distribution verified prior to placement on the eye.

2.1.1. OCULAR MALIGNANCIES
In adults, the most common ocular malignancy is uveal or intraocular melanoma,
followed by lymphoma of the eye [15]. In children, Retinoblastoma is the most
common (although it is rarely found in persons over the age of 5), followed by
medulloepithelioma. Intraocular cancers are rare compared to other forms of
malignancies, and there are only around 0.1 to 2.3 cases of intraocular melanoma per
100,000 people world-wide [16]. Contrary to other malignancies, such as the more
common form of melanoma, skin cancer, no major causal factors have been found,
despite years of research into the condition.

2.2. EYE PLAQUES
Currently, there are two I-125 based eye plaques commonly used for the treatment of
intraocular melanoma. These are the COMS (Collaborative Ocular Melanoma Study)
eye plaque and the ROPES (Radiation and Oncology Physics and Engineering
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Services, Australia) eye plaque. Many studies have been completed to evaluate
current methods of dosimetry used to verify the administered dose of the COMS eye
plaque [4],[17]. However, there is limited research regarding the dosimetry of
treatment using the ROPES eye plaque and custom eye plaques [15], [16]. The
ROPES plaque is manufactured in Australia [18] and so is the more accessible and
more commonly used of the two in this country. For these reasons, it is the ROPES
eye plaque which is investigated in this study.
As enucleation and eye plaque brachytherapy have similar tumour control statistics,
one of the advantages of using eye plaque brachytherapy as a treatment modality for
intraocular melanoma is the potential to avoid vision impairment of the patient [20].
However, radiation damage to the critical structures in the eye (including the retina,
optic nerve and lens) can cause vision losses, negating one of the most advantageous
aspects of the treatment modality. Thus, accurate dosimetry of eye plaque
brachytherapy is then essential in order to ensure the sparing of the aforementioned
critical structures.
Many studies have been conducted regarding eye plaque brachytherapy dosimetry.
Among these, many have been completed using an I-125 source. However, there are
also comparisons between sources to be made. These studies, pertaining to source
utilisation and success rates, are summarised in Appendix 1.
.

2.2.1. SOURCES
In the past, there have been various brachytherapy sources used in eye plaques.
Since the first use of Radon seeds [4] in brachytherapy, other sources such as I-125,
Co-60 and Ru-106 [10] have become increasingly popular. One reason for the
popularity of I-125 in particular, is that it’s comparatively lower photon energies
(28.3keV, as opposed to Co-60 which has photo peaks at 1.17 and 1.33 MeV) allow
sparing of the surrounding critical structures. Table 1 gives various energies and
other considerations of common eye plaque brachytherapy sources.
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Table 1- Brachytherapy sources and some factors that affect treatment. Adapted from
[11]

Source

Half Life (days)

Average Energy

Cost

HVL in Water

(MeV)

(mm)

I-125

59.6

0.025

medium

20

Co-60

1916.25

1.25

low

108

Ru-106

367

3.5 (Beta)

high

24

Ir-195

74.2

0.38

low

63

Pd-103

17

0.021

medium

15

From Table 1, it can be seen why particular sources are so desirable for use in eye
plaque brachytherapy. For example, I-125 is now used because of its low average
energy and HVL (Half Value Layer) in water. This ensures the tumour receives most
of the dose, with minimal dose being received by critical structures. Using this
criteria alone, one would believe that Pd-103 would also be a desirable candidate.
However, the short half life of this isotope provides only a small window of time in
which it may be used for treatment, which is reduced further if dosimetric
measurements are to be conducted prior to treatment. The short half-life also means
that the known activity of the isotope will change quickly, with only hours making a
significant difference, and as a result, will be more difficult to plan for.

7

There are currently many commercially available brachytherapy sources. Many of
those used for prostate brachytherapy can also be used in eye plaque applications. In
this study, Oncura Thinseed (Model 9011) and Isoaid Advantage seeds (Model IAI125A) were used with the most frequency. As shown in
Figure 2, the main difference between the two types of seeds is their size. This must

be accounted for when any calculations are to be completed and both models have
been used. This will be discussed further in the following chapters.

8

Figure 2- Size comparison of both the seed and the active volume of a. the IsoAid Advantage
I-125 and b. the OncoSeed Thinseed 9011. Adapted from [22] and [23]
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2.2.2. THE TG-43 FORMALISM
In 1993, the American Association of Physicists in Medicine (AAPM) published
recommendations for Low Dose Rate (LDR) Brachytherapy dosimetry calculations.
Among other uses, these guidelines can be used to calibrate detectors and calculate
doses in I-125 eye plaque brachytherapy. Task Group 43 (TG-43), a task group
designated with this specific task, determined the published guidelines [24], and
further updated these recommendations in 2004 [25] to include relevant source data
and corrections to the calculation nomenclature
As I-125 brachytherapy seeds are used for all aspects of this research, all sources are
considered to be cylindrical. In this case, it is the recommendation of the TG-43
report that the source dose rate be expressed in terms of separable two dimensional
functions, in this case expressed as [19],[24]:
(1)

Where r is the distance from the centre of the seed to the point of measurement, is
the angle subtended by the line joining the centre of the seed to the point of
measurement and the seed axis, λ is the dose rate constant,

is the geometry

function, with the subscript “L” indicating that line geometry was used due to the
brachytherapy seeds being of cylindrical dimensions, λ describes air kerma strength,
gL(r) is the radial dose function, F(r,θ) is the anisotropy function and

is the

reference point, with radial distance being 1cm and the angle to the seed axis being
90°.
Each of these functions can be simplified individually as per TG-43 report
suggestions [24]:
I.

Air Kerma strength is a measure of the radioactivity of the source and is given
by:
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(2)

Where

is the air kerma rate in a vacuum for photons greater than energy δ

and d is the distance from the source on the transverse axis of the source. The
units of air kerma strength are
II.

or U.

The radial dose function, g(r), takes into account the attenuation and scatter in
the medium and hence, the decrease in dose with distance to the source. It
uses a reference point of

, which is used in later experiments for

calibration of detectors. To calculate the radial dose function at a given point,
the following equation is used:

(3)

Where the subscript X represents either the line source (L) or point source (P)
approximation used for the geometry factor.
III.

The Geometry function, G(r,θ), accounts for the spatial distribution of the
source relative to the calculation point. It is simplified using one of two
methods. The first is the point source approximation which may be used
when measuring dose at a relatively large distance from the source. The other,
which is used throughout this research is the line source approximation,
given in equations 4 and 5:

(4)

(5)
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Where L is the length of the seed, and β is the angle of measurement as shown
in Figure 3.

Figure 3 Geometry Factor, Adapted from [19]

IV.

The Anisotropy function, F(r,), accounts for the variation in dose with angle
about the seed due to the encapsulation of the course within the capsule. The
function is described as:

(6)

This equation is only used when the Geometry factor is approximated using
the line approximation, rather than the point source approximation.

In the following chapters, TG-43 guidelines are referred to for most calibrations.
These formal guidelines are the basis of dose rate calculations. According to these
guidelines, each calibration must be completed using a source of known activity, at a
distance of 1cm from the specified detector.
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To complete these calculations, many factors are taken into account. Although many
of these are discussed in later chapters, one of the most important factors that must
be accounted for is the dimensions of the seed. The active length and width, the
length and width of the whole seed and the angle at which it sits in relation to the
detector all influence the calibration and dose calculation.
TG-43 is an accurate analytical evaluation of the dose from brachytherapy sources.
Despite this, a significant amount of scattering occurs from the backing of the eye
plaque [28]. Although this phenomenon has been published in the past, the research
has been conducted only with COMS plaques and therefore a gold backing. TG-43
based planning has been found to underestimate the dose within the eye by as much
as 10% [25] in COMS plaques. An advantage of ROPES plaques in this regard is that
the scatter from the steel backing, being less dense than gold, will produce less
backscatter, and result in a smaller deviation in results from the analytically derived
TG-43 comparisons.

2.3. DOSIMETRY FOR EYE PLAQUES
There are currently few dosimetry methods for eye plaque brachytherapy. The
methods mentioned in the literature include Monte Carlo simulations [5], TLDs [31],
Gafchromic film [37], and most recently, spectroscopic dosimetry has been theorised
[18]. Despite the various methods for eye plaque dosimetry, there is no method
which can be conducted prior to the surgical implantation to ensure correct dose
distribution. Methods have been theorised by Weaver et al 2011 [17] and Cutajar
2011 [19].

2.3.1. TLDS
In the past, Thermoluminescent Dosimeters (TLDs) have been the detector most
commonly used for the dosimetry of eye plaque brachytherapy [14],[31]. They were
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chosen because of their small size and ability to be used as passive detectors. That is,
they can be left in the radiation field and the absorbed dose determined at a later
time. However, the eye is a small organ (with a radius of around 12mm), and the
critical structures within it smaller still, with the lens being around 9mm in diameter
[29]. It is believed that TLDs do not give the spatial resolution required to determine
whether the critical structures within the eye are being spared or not [33].
TLDs are most commonly made from either Lithium Fluoride (LiF) or Calcium
Fluoride (CaF) crystals. These crystals are able to store charge as shown in Figure 4.
When ionising radiation is incident on the detector, electron hole pairs are formed.
However, unlike scintillator materials, these electron hole pairs are temporarily
immobilised in electron or hole traps [31]. These “traps” occur in defects of the
crystal structure [30].
In order for the recombination of these electron hole pairs to occur (Figure 4), the
crystals must be heated through a readout process of heating. Because the electron
and hole traps formed in the detector are relatively stable (however, fading will be
experienced over multiple days [32]), they are used in the radiation field passively,
and the charge measured at a later time. These dosimeters are reusable. However,
before they can be reused, they must first undergo an annealing process.
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Figure 4- a. The formation of electron and hole traps with incident ionizing radiation on the
crystal. b. The two ways in which recombination, and luminescence occurs. Adapted from
[30]

Fading is experienced by a TLD when the readout is delayed after irradiation. Some
electrons and/or holes are released from the traps spontaneously, without the
heating process being necessary. This may result in a result lower than the real value
[30].
Although TLDs are advantageous due to their ability to be small in size, come in
various forms (Figure 5), have near tissue equivalence (in the case of LiF) and ability
to work in a passive capacity, they are also at a significant disadvantage in terms of
reproducibility, time and ultimately, cost [30]. TLDs require a long process of
readout in order to get the luminescence which is used to determine dose, which can
be a major inconvenience [33]. Although unlikely, errors in this process may easily
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cause major inconsistencies in results. Another disadvantage of using TLDs for eye
plaque dosimetry is the instability that can be experienced by TLDs over time,
causing inconsistency in readouts [33].
Another, more general disadvantage of TLDs is that, although they can be used in a
passive capacity, they cannot be used also be used in an active mode. This simply
means that TLDs cannot be used as real time dosimeters while dose is accruing, as
they are read out using a reader, removed from the radiation source.

Figure 5- TLDs in various forms. This diagram shows rods powder and chips, however,
other forms and sizes are commercially available [32]

Results gained for the dosimetry of eye plaque brachytherapy using TLDs in the past
have provided consistent and reliable data [27]. However, because of the
characteristics described previously, if dosimetric data was required immediately
before the surgical implant of the eye plaque, it cannot be provided. In some
situations, this information may not be necessary. However, in others, especially
those involving custom eye plaques, real dosimetric data, rather than planning
system data would be useful.

2.3.2. GAFCHROMIC FILM
Gafchromic film has been used in the past for the dosimetry of eye plaque
brachytherapy [37],[38]. Film has similar advantages and disadvantages as TLDs in
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terms of being used in a passive sense, the small size and the near tissue equivalence.
Gafchromic film is analysed on a comparative basis. That is to say, that a known
dose can be seen on the film after a certain development time. For development to
complete or stabilise, there must be a period of approximately 24 hours [36] between
irradiation and analysis. Faster analysis of this data would greatly benefit the
dosimetry of eye plaques.
Gafchromic EBT 2 film is a type of radiochromic film commonly used in dosimetry.
Radiochromic film is composed of clear polyester, coated on one or both sides with a
radiosensitive emulsion, finished with an adhesive layer and clear sealant to prevent
damage to the radiosensitive layer [39],[40],[41]. The composition of the Gafchromic
EBT2 film is shown in Figure 6.

Figure 6- The composition of Radiochromic, including Gafchromic film. Adapted from [40]

After Gafchromic film is irradiated, it is scanned, with the relative intensities of the
irradiated film giving the dosimetric properties of the exposure. These are used in
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audits such as in [41],[42]. With each batch of film a density to dose calibration curve
is established by exposing films to known doses and measuring the optical density
or pixel value at each dose increment, which will later allow the effective
measurement of dose via image comparison. However, as every batch has the
potential for variation, each batch must be calibrated individually.
Gafchromic film is favoured in dosimetric applications for many reasons. In QA, the
most common reason for Gafchromic film to be used above other films (such as
radiographic film consisting of a silver halide emulsion which also requires
development) is that it has near tissue equivalence. However, other features of the
film such as sensitivity to visible light, water resistance, development method and
sensitivity to radiation. It is these that make Gafchromic film particularly viable in
dosimetric applications.
It is the near tissue equivalence (due to its atomic number, Z and density) at doses in
the MeV (Mega electron Volt) energy range that allows Gafchromic film to be
included in a phantom without disrupting the beam in a way other than that which
tissue (or the material surrounding the film) would [43],[44],[45]. Tissue equivalence
of Gafchromic film is mentioned by numerous authors and is why this particular
film is used so frequently. However, according to [41], at lower energies (in the keV
range), the film no longer presents a near tissue equivalence.
Using film as a method of eye plaque dosimetry has proven to have benefits in the
past. As it can be used in a passive capacity, film can be inserted into a phantom and
the resultant dose to the film determined after irradiation has occurred. This was the
basis for the ICARIS (Inter Comparison of Australian Radiotherapy IMRT Systems)
project conducted by the ICCC (Illawarra Cancer Care Centre) in 2011 [42].

2.3.3. CALIBRATION OF GAFCHROMIC FILM
Calibration of Gafchromic film for brachytherapy dosimetry experiments, is similar
to that of MOSFETs (as described in Chapter 3). Film is irradiated by a source of
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known activity at a known distance for a particular time. When this is analysed, the
colour change seen in the film represents a dose on the film that can be calculated
from the known values. When this is repeated with different times, activities or
distances, a trend can be determined.
Gafchromic film performs linearly with increasing dose. As a result, a calibration
factor can be obtained which will allow the determination of the dose incident on
any film of the same batch. This will be further explained in Chapter 3. It should also
be noted that the film becomes stable after 24 hours and so should always be
scanned at the same time after irradiation.

2.4. SCLERAL DOSE
Scleral necrosis is one known side effect of treating intraocular tumours using eye
plaque brachytherapy. It is not common as the sclera is quite radio-resistant [46],[45].
However, it is important to minimise the risk of such an occurrence in order to
prevent enucleation [46]. Currently, the only method used frequently in the
verification of scleral dose to the patient is by a dose calculation algorithm, as
recommended by the AAMP TG43 [24].
In the past, various institutions have researched absorbed dose from eye plaque
brachytherapy using water phantoms and silicon diodes [53] or Gafchromic film
[38]. However, these institutions have not focused their attention on the scleral dose,
but rather verified the planned dose to the tumour.
One of the aims of this study is to determine the scleral dose to a patient undergoing
eye plaque brachytherapy typical of most Australian radiotherapy treatment centres.
Employing eye plaque brachytherapy. As a result of this, it is hoped that further
research will go into investigating and recommending dose limits for the sclera. This
will hopefully reduce the number of cases in which scleral necrosis is observed as an
after effect of irradiation. The structure of the eye is shown in Figure 7.
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The American Brachytherapy Society (ABS) recommends a prescribed dose to the
apex of the tumour of 85Gy and the recommended dose rate using I-125 between 0.6
and 1.05Gy/hr, resulting in a treatment time of 3-7 days. However, this
recommendation does not specify the dose limits to the sclera. One of the difficulties
in estimating the dose to the sclera is the largely differing dimensions of ocular
malignancies. A tumour with a deeper apex with the same prescribed dose will
result in a much higher scleral dose than a tumour with an apex closer to the surface,
due to the steep dose gradient [25].
There is little literature focused on the occurrence of scleral necrosis after eye plaque
brachytherapy, and as such there are few readily available statistics to verify the
number of patients who develop the condition. Despite this, it is mentioned in
several studies that scleral necrosis is a risk factor during treatment [45], [51]. This
may be explained by the inability of eye plaque brachytherapy planning to limit the
dose to the sclera whilst treating the tumour, as is the nature of the treatment
method.

Figure 7 Structure of the Human Eye [46]
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2.5. MOSFET DOSIMETRY
Metal Oxide Semiconductor Field Effect Transistors (MOSFETs), as the name
suggests, are semiconductor detectors. They are currently used as a reliable method
of in-vivo dosimetry of external beam radiation therapy [48] and can be a more
convenient choice than Thermo-Luminescent Detectors (TLDs) in the clinical
environment when reproducibility and immediate readout are required [3].
Although first suggested as early as 1925, MOSFETs have only been in existence
since the 1960’s, and have only recently become recognised for their potential for a
range of detection [49].
The response of a MOSFET detector depends on the following factors (from [50]):


The gate oxide thickness



The electric field on the gate oxide during irradiation



The energy and linear transfer of the impinging radiation

2.5.1. MEASUREMENT OF RADIATION FIELDS USING MOSFETS
MOSFETs are semiconductor detectors which utilise the principle that the changing
threshold voltage (the voltage required to induce a fixed current flow between the
source and the drain) is directly proportional to the ionising radiation incident on it.
The ionising radiation incident on the detector (in this case, gamma radiation from
an I-125 source) causes electron hole pairs to form in the Silicon Oxide layer (Figure
8) [30].
When a MOSFET is used in active mode, as in later chapters, a positive bias voltage
is applied to the detector. This bias voltage forces most of the electron hole pairs
which have formed under the metal gate (Figure 8) to separate, with the electrons
moving toward the gate contact and the holes toward the junction between the
Silicon Oxide gate and silicon substrate. If the MOSFET is first calibrated against a
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known radiation source, the dose received by the detector can be measured
effectively [30].

Figure 8- A Simple MOSFET Design [51]

The measured radiation dose comes from a shift in the measured threshold voltage.
Electron-hole pairs are generated in the silicon oxide layer by exposure to ionising
radiation. The holes, or positive charge is trapped at the SiO2-Si interface, as seen in
Figure 8. When a bias voltage is applied during irradiation of the device, the shift in

the IV characteristics is linear with dose. This shift is demonstrated in Figure 9.
As previously mentioned, the MOSFET device may be operated in active mode,
whereby there is a positive bias effective on the gate during operation, or passive
mode, where no bias voltage is present. The change in threshold voltage, ΔV is
represented by equations 8 and 9 respectively.

f

(8)

f

(9)
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Figure 9- The observed shift in threshold voltage of a MOSFET detector [51]

In summary, MOSFETs work as ionising radiation creates positive charges in the
gate oxide of the transistor, which are stored at the substrate-oxide interface leading
to a threshold voltage shift in the transistor. This charge is stored using the
capacitance of the device and read out using a small current after irradiation (if used
in passive mode) or in real time (if used in active/online mode) [52]. The structure of
a MOSFET can be seen in Figure 8.

2.5.2. CURRENT USES OF MOSFETS
MOSFETs are currently used in both clinical and research settings as they provide
accurate data, as well as being small and easy to use. Amongst other clinical uses, a
new MOSFET detector, called MOSkin, has been developed at the Centre for Medical
Radiation Physics, University of Wollongong, to measure the skin dose to a patient
during external beam radiotherapy [52].
There are ongoing developments into the uses of MOSFETs and they are being used
heavily in other current brachytherapy research. As these detectors are further
developed, they are being made more and more viable to clinical adaptations.
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2.5.3. ADVANTAGES OF THE MOSFET
There are many advantages to using MOSFETs to calculate the dose received by a
patient. Many of these advantages are shared with other detectors such as TLD’s.
However, there are many other features which make MOSFETs unique, and hence,
marketable as a sound alternative to other detectors, previously used in similar
applications.
In the past, characteristics such as reproducibility, linearity, angular dependence,
energy dependence, SSD dependence and field size dependence have been tested in
MOSFETs and compared to results from TLDs [50] (the most common form of
detector used when undertaking dosimetry of eye plaque brachytherapy), and have
shown favourable results. This further emphasised some of the advantages of the
MOSFET detector.
Some of the major advantages of semiconductor detectors in general include (from
[45],[22] and [55]):


Low cost



Higher sensitivity than ionising chambers of the same volume (approximately
18000 times)



A small dosimetric volume size and weight



Good mechanical stability



The ability to operate in either a passive mode or an active or on-line mode



Information retention with resistance to “fading” effects



High accuracy



Sensitivity to low energy radiation (including brachytherapy)
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Possible integration with other sensors and/or circuitry

2.5.4. DISADVANTAGES
One of the challenges presented in dosimetry with a MOSFET detector is the
temperature dependence of the threshold voltage [52]. This is mostly determined by
temperature dependence of the charge carrier mobility in the p-Channel of the
MOSFET. This temperature instability coefficient ΔVth/T depends on readout
current and can be positive or negative of the order of 0.3-.0.8 mV/°C, which is small
compared to the sensitivity of MOSkin detectors, having a sensitivity in the order of
7mV/cGy for I-125 photon spectra energies.
Methods to avoid temperature dependence in the MOSFET detectors include dual
MOSFET detectors produced on the same chip close to each other and operating
under different gate bias. Readout is then completed in subtraction mode, avoiding
temperature effect while giving usable dose signal [52]. Another method is to use the
readout current corresponding to zero temperature instability [53], a specific
threshold current which corresponds to a constant voltage, over a varying
temperature range.
MOSFET detectors, as with many other integrated detectors like TLDs and film, are
subject to fading, i.e. changing of ΔVth in time after irradiating due to room
temperature annealing. This fading is not large and depends on technology and can
be up to 5-7% per year. However in case of real time readout fading is generally not
an issue as the results are obtained immediately before fading has occurred.
MOSFET detectors are reduced slightly in sensitivity with accumulated dose that can
be taken into account by rechecking calibration after each 10 Gy until limited
accumulated dose has been achieved.
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2.6. MOSKIN
The particular MOSFET device used in this study was a MOSkin. The main reason
for using the MOSkin device was that it is designed for use in surface dose
measurements [54]. As in this study required scleral dose measurements, it was an
ideal dosimeter.
Some of the other reasons that a MOSkin dosimeter is useful for surface
measurements include that the results are reproducible and show little angular
dependence compared with the MOSFET [54].
The main difference between a conventional MOSFET and the MOSkin is the method
in which the sensitive volume of the detector is encapsulated, as seen in Figure 10
Traditional MOSFETs have the detector set in an epoxy bubble, with MOSkins using
a Kapton layer, ensuring the sensitive volume is a standard 70 microns water
equivalent depth from the surface. This assurance of distance results in consistent
and reliable surface dose measurements, as per ICRP recommendations [59].
Investigations have been undertaken to determine the usability of MOSkins for
quality assurance measurements in HDR brachytherapy with promising results [52],
but have seen very little use in treatments which employ LDR brachytherapy
sources.
Build-up Layer
~0.8mm

Epoxy Bubble MOSFET

MOSkin

Figure 10- MOSFET with Epoxy bubble, compared with the uniform Build-up layer of the
MOSkin [54].
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2.7. SPECTROSCOPIC DOSIMETRY
Spectroscopic dosimetry involves the analysis of the spectra from known isotopes to
estimate the incident dose rate. The principle of spectroscopy can be applied to
determine the energy of ionising radiation incident on a detector operating in
spectroscopy mode, as long as the isotope and respective energy spectrum is known.
The spectroscopic dosimetry system registers an approximate dose rate by
integrating the number of events corresponding to the photopeaks of the isotope
[57], [18]. As spectroscopic dosimetry analyses the incident radiation on a pulse by
pulse basis, it greatly improves the sensitivity of semiconductor detectors in low
dose rate fields, as opposed to traditional semiconductor dosimetry methods, which
rely on an induced current within the detector. In the scope of this project,
spectroscopic dosimetry is examined as a prospective tool for use in future quality
assurance (QA) tests for eye plaque brachytherapy, based on the high sensitivity,
immediate readout and the possibility of small detector size. By considering only the
counts which occur at the known emission values for Iodine-125, the counts which
are due to background and scattered radiation within the detector, as well as noise
can be discarded.
This dosimetry method is not necessarily useful for any radioisotope. If the spectrum
of the radioisotope is not monoenergetic, spectroscopic dosimetry will not register
an exact dose, as different energy peaks deposit varying amounts of energy, which
will lead to an incorrect dose rate measurement at different depths that used
calibration, as the relative peak heights across the spectrum will change with depth.

2.7.1. IODINE-125
Iodine 125 has a photon emission spectrum of four peaks, two major, two minor at
35.5keV, 27keV, 32keV and 31keV [47]. However, as the brachytherapy seed is an
encapsulated I-125 source, there are additional fluorescent peaks at 22keV and 25keV
from the silver rod within the brachytherapy seed. The unique property of the I-125
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isotope which makes it ideal for dose rate measurements using spectroscopic
dosimetery is the spectrum. The spectrum emitted from I-125 shows multiple energy
peaks, close together, with the most intense peak (27keV) central to the remaining
peaks, as shown in Figure 11. Although not strictly a monoenergetic spectrum, it is a
near enough approximation to gain accurate results from a spectroscopic dosimeter.
It is the intensities of the peaks in the measured I-125 spectrum which are an
indication of the deposited dose rate [58]. When measured using spectroscopic
dosimetry, the dose received at the point of measurement by a patient undergoing
low dose rate (LDR) brachytherapy from I-125 sources can be found.

Figure 11- I-125 spectrum, from an Oncura 6711 seed, showing the two most prominent
peaks, measured with a silicon detector. Courtesy of Dean Cutajar [50].

Any spectra obtained for a radioactive source is established from the counts incident
on the detector. For this reason, it can be a very accurate tool for dosimetry. By
acknowledging only the counts which occur at the known emission values for
Iodine-125, the counts which are due to background and scattered radiation within
the detector, as well as noise can be dismissed. This concept holds true if the peak
heights do not vary relative to each other. If this is the case, an average
attenuation/mass absorption coefficient can be assumed. This is shown in section
6.3.2.
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3. CALIBRATION OF MOSFET DETECTOR
The response of a MOSFET detector is dependent on the energy of the photon
radiation it is detecting, as the devices are based on silicon, hence are not water
equivalent. For high energy photon sources, such as in external beam radiotherapy,
MOSFETs are less sensitive per unit dose in water than the low energy photon
sources used in eye plaque brachytherapy (I-125), as the sensitivity of the detector is
increased greatly due to stronger photoelectric-effect in the SiO2 gate at these
energies in comparison to water. This is an advantage for the measurement of low
dose rate radiation in comparison with dose verification of LINAC treatments, as is
the case of eye plaques. For this reason, the response of the MOSFET detector must
be calibrated with a source of the same energy distribution that is to be investigated.
As the MOSFET used throughout this research, the MOSkin, is used for eye plaque
brachytherapy, it was calibrated according to the TG-43 protocol, using an
individual I-125 seed similar to those mounted in the eye plaque, of known activity.
MOSkins have a measurement error of approximately 1% in this dose range, and as
the same detector was used for both calibration and measurement, it is the error
incorporated into the following experimental results.

3.1. METHOD OF DETERMINING THE CALIBRATION FACTOR
The experimental setup to determine the calibration factor of the MOSkin employed
in this study contained a solid water phantom, into which a single Oncura Thin Seed
(Model 9011) brachytherapy seed of activity 0.289mCi was inserted. The phantom
was machined in such a way that the centre of the seed was located 1cm from the
surface, where a MOSkin was affixed. The setup was surrounded by at least 4.5cm of
solid water in each direction, with additional PMMA in each direction surrounding
the setup to provide adequate backscatter conditions. A diagram of this is seen in
Figure 12.
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Figure 12 Experimental setup, with a surrounding medium of Solid Water,
extending a minimum of 4.5cm in all other directions from the brachytherapy seed,
with additional PMMA used for appropriate backscatter

Over time, the voltage change in the MOSFET can be observed. It is this voltage
change that is directly proportional to the dose the detector is receiving. This is
evidently the case when a straight line is produced when plotting the voltage change
of the MOSFET against time. This can be seen in Figure 13, and is further explained in
the proceeding section.

3.2. RESULTS
The activity of the Oncura Thin Seed (Model 9011) used for the calibration was
determined to be 0.289mCi, as the activity was known to be 0.4mCi 28 days previous
to the calibration, using the formula:
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(10)

Where

is the initial activity, λ is the decay constant of the radiation source (as the

I-125 seed used has a half-life of 59.4 days, the decay constant was 0.012 days-1) and t
is the time which has lapsed since the source was at its original activity.
Having a known seed activity, a TG-43 formalisation can be used to calculate the
dose the detector will be receiving per hour of exposure. From the two dimensional
model, there are four factors that represent the main differences between the seed
models: The source length (the length of the source within the capsule, not the seed
length itself), the dose rate constant, the radial dose function and the anisotropy
function. The TG-43 parameters used in conjunction with equation 1, to calculate the
dose rate at the location (1cm,90°) from the model 9011 thinseed, were obtained from
the data within [26], with the radial dose function being 1.00, the 2D anisotropy
function being 1.00, the source length being 2.79 mm and the dose rate constant
being 0.918 cGy

[23].

The dose rate incident on the detector was found to be 1.38cGy/hr. This can be used
with the gradient of the line in Figure 13, found to be 0.0089V/hr to determine the
relationship between MOSFET and absorbed dose.
These results are shown graphically in Figure 13, with the gaps in data representing
overnight measurements where repeated readouts were not possible.
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Figure 13- The response of a MOSFET to a known radiation source over time. The error in
readings was approximately 1%.

Using the gradient of the above graph, the change in threshold voltage relative to
time was found to be (9.00 ±0.09) mV/hr, and from above, the known dose rate
incident on the detector is 1.38cGy/hr. As a result, the dose rate is found as follows:

(11)

(12)

32

The energies used for calibration, and the calibration values are within the expected
range for MOSkin calibration, according to Lian C. P. L. et. al. [62]. This author has
established the validity of the MOSkin in x-ray fields of ranges 30-120 keV, and
provided an estimate of the range of expected calibration values, although some
variation between MOSkins is expected. As a result, the above calibration is
considered valid for future calculations.

3.3. DISCUSSION OF PRACTICAL IMPLICATIONS
The American Brachytherapy Society (ABS) recommend the dose to the apex of an
ocular tumour over the time in which it is left on the eye to be approximately 85Gy,
and the recommended dose rate using I-125 between 0.6 and 1.05Gy/hr, resulting in
a treatment time of 3-7 days [22]. Considering the low activity of the seeds being
used (between 0.34 and 0.28mCi), it is unrealistic to continue to measure calibration
points after a 500mV change is observed, due to the changing activity of the seeds.
Comprehensive Results are extrapolated, for doses falling above those observed
during calibration of the detector.
Using this theory, alongside corrections for the decay of the radioisotope, it is
possible to determine the location of the maximum scleral dose as well as what the
maximum scleral dose may be during treatment. This may be important as, if the
somewhat high radiation tolerance level on the sclera is exceeded, there may be
profound negative consequences. One such consequence (discussed in Chapter 1) is
scleral necrosis, a disease that causes tissue death in the sclera and may ultimately
lead to the enucleation of the eye.
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4. SCLERAL DOSE MAPPING
After determining the calibration of the MOSkin, it was used to determine the
location of, and the maximum dose administered to the sclera during eye plaque
treatment. To achieve this, an acrylic eye phantom of diameter 24 mm was used, as
shown in Figure 14, in which the MOSkin was placed in each area of interest.

Figure 14- Eye Phantom

4.1. METHODS
4.1.1. MAXIMUM SCLERAL DOSE RATES
It is expected that the maximum dose received by any single point of the sclera will
be located directly underneath one of the seeds, specifically one of the inner seeds.
To find the maximum dose to any point on the sclera, a MOSkin was placed under a
fully loaded 15mm ROPES eye plaque at various locations, observing a change of at
least 600mV at each location. As shown in Figure 17, the MOSkin was placed under
each seed (1-10) to find the maximum scleral dose, as well as 13 other locations
between the seeds and around the plaque periphery (A-M).
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Figure 15- Labelled MOSFET Positions under Eye Plaque.

4.1.2. SURFACE DOSE UNDER PLAQUE
The scleral dose map of the eye plaque was completed by placing the MOSkin in the
areas between the seeds and around the plaque periphery, as seen in Figure 15, in
locations A-M. This is not a measure of where the lowest dose received was located,
but rather a way of observing any difference between the dose received by the sclera
directly under a seed to the sclera under other sections of the eye plaque.
The scleral dose map is designed to show the differences of dose on the sclera, with
the results showing the changing dose rate according to the proximity of the location
to the seeds.
35

Beyond the edge of the eye plaque, it is expected that there be little dose received by
the sclera due to the stainless steel backing. Although the plaque is not designed to
irradiate the area, the scatter from the plaque will result in a small dose. If a high
dose were to be observed, it would indicate that the backing of the eye plaque was
not shielding as it is designed to, and could possibly imply a poor outcome in terms
of the surrounding tissue. Due to this, it is assumed that there will be a noticeable
difference between the MOSkin positions in the centre of the eye plaque, compared
to the periphery positions K, L and M.
It was previously mentioned that measurements were not necessary beyond a
change of approximately 500 mV. A maximum of 3.5 hours was required to obtain
data for points in the periphery, whereas a minimum of 1.2 hours was required to
obtain adequate data in points underneath seed locations.

4.2. RESULTS
4.2.1. MAXIMUM SCLERAL DOSE RATE
The activity of the IsoAid Advantage I-125 seeds used for determining the scleral dose
was determined for each day of experimentation to ensure that the determined dose
was accurate, before being normalised to 0.4mCi for comparison. The measurements
of the scleral dose were taken over the course of a 6 week period.
TG-43 calculations were performed to calculate the expected dose rate to point A. A
superposition of the dose rates at the point of measurement from all seeds gives the
total dose rate at the point of measurement. The parameters used to determine the
TG-43 data for the IsoAid Advantage I-125 seeds were obtained from [26]. As point A
is along the central axis of the plaque, the point of measurement is always along the
transverse axis of every seed in the plaque (90°), therefore the anisotropy function
value was 1.00. The source length for each seed was 3mm and the dose rate constant
was 0.995

[26]. The radial dose function value for each calculation was

determined by interpolating the radial dose function data, shown in Table 2.
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Table 2 Radial Dose function variation with radial distance, adapted from [26]
Radial Distance (cm)

Radial Dose Function

0.5

1.08

1

1

1.5

0.902

2

0.8

2.5

0.701

3

0.611

3.5

0.533

4

0.468

4.5

0.414

5

0.368

6

0.294

7

0.227

8

0.165

9

0.141

The Dose over time incident on the detector from each position, as expected forms a
straight line, showing a linear MOSFET response. It is the gradient of the line in
Figure 16, along with the calculated dose rate incident on the MOSkin.
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Figure 16- The MOSkin response over time in position 1, with an error in MOSkin reading of
1%.

From Figure 16 the dose rate must be determined using the MOSkin calibration factor.
From the calibration factor of 6.52 mV/cGy, the measured response was converted
to dose, as shown in Figure 17.
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Figure 17- Dose vs. time for a fully loaded ROPES plaque in position 1, with seeds of

activity 0.282mCi, normalized to 0.4mCi with an experimental error of
approximately 1%

The gradient of Figure 16 gives the dose rate incident on the MOSkin as
28.279cGy/hr. As the seeds are decaying over time (as demonstrated above), this
must be converted into a dose rate with a set activity for comparison. As the I-125
brachytherapy seeds were 0.4mCi when they were first used for this project, this has
become the reference activity throughout this report. Using the following equation,
for a source activity of 0.4mCi, the dose rate is determined to be 40.11cGy/hr at
position 1 using equation 13:

(13)

Where A is the known activity of the source and
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is the dose rate.

After the correction for dose rate has been made, the results can be compared. The
comparative results for the scleral dose rate measured underneath each of the 10
seed locations, and can be seen in Figure 18.
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Figure 18- Dose Rate in various scleral positions normalising the source activity to 0.4mCi,
as calculated using Equation 12. Error is estimated from error associated with MOSkin
detector.

4.2.2. SURFACE DOSE UNDER PLAQUE
The results show that there is a slightly higher dose rate in positions directly
underneath the seeds, with the exception of location 2. However, beyond the edge of
the eye plaque, the dose rate is significantly lower, as shown in Figure 19.
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Figure 19- Dose rate to MOSkin situated under particular positions of an eye plaque using
sources simulating an activity of 0.4mCi (Equation 12). Error derived from potential error in
measurement in the MOSkin
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Figure 20- Average Dose Rate (cGy/hr) of each of the 23 positions previously mentioned,
assuming a seed activity of 0.4mCi. The error within in each of these readings is
approximately 2%, when combining MOSkin measurement error and potential positional
error.

It can be seen from the results (Figure 20) that the dose received by the sclera over
time is more uniform directly under the plaque than expected, with the exception of
the peripheral locations. However, when the scleral dose is measured at the edges of
the plaque, as is the case for positions K, L and M (from Figure 15), there is a
significant drop in the dose received in that area. This is to be expected as it is
intentionally planned to be the case in eye plaque brachytherapy. If there was a high
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dose at the edge of the eye plaque, the sclera, as well as the tissue encasing the eye
would receive a much higher than anticipated dose.
The expected surface dose at point A, as calculated using the TG-43 formalism, was
95.54cGy/hr/mCi. Therefore, the surface dose rate for 0.4 mCi seeds was expected to
be 38.216cGy/hr at this point. Experimentally, the dose rate at this point was found
to be 36.3 ±0.5 cGy/hr. Discrepancies between the two values may be due to the
limitations of the analytical calculations caused by the presence of stainless steel in
the plaque backing, reducing the dose through a reduction in backscatter, a small
misalignment in MOSkin placement, as well as limitations in the TG-43 formalism
when calculating in close proximity to the seeds.

4.3. DISCUSSION
4.3.1. MAX SCLERAL DOSE RATE
When observing the scleral dose under each of the seeds, it can be seen that there is a
similarity in the data, with an anomaly at position 2. That is, that the dose received
by the MOSkin under each of the seeds is within the calculated error of all other
results. There is one exception to this, and that is when the MOSkin was placed in
position 2, which could be due to a placement error of the plaque relative to the
MOSkin, a lower activity seed within the batch, or a combination of the two.
Another explanation of his is that the errors in the placement of the plaque, although
only sub-millimeter may have resulted in a change in dose rate of several percent. In
this case, the expectation that the seed activity being lower than the others is
unlikely, as the activity of the seeds is determined upon delivery. The clinical
implications of seeds of varying activities would also be significant.
4.3.2. SCLERAL MAP
The results show that mapping the surface dose using eye plaque dosimetry can be
completed with very accurate results. This can be verified by observing the close
agreement with the TG-43 analytical results.
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The results from this research show that at the surface, only a slightly greater dose is
observed in the areas directly under the brachytherapy seeds, with the differences
being 5% at most. The areas under the gaps in the plaque showing a lower dose rate,
as expected. This is valuable information that can be used for the verification of
treatment planning, in cases in which scleral necrosis is a possibility, and the
differences seen may be due to a combination of limitations of the TG-43 formalism,
misalignment of MOSkin placement and backscatter from the plaque backing.
Surface dose mapping has been shown to be achievable using a MOSFET based
dosimeter, the MOSkin. In order for dose mapping of the sclera to become a useful
tool in terms of treatment planning, however, it would be more convenient for the
dose mapping to take place in real time.
Currently, scleral dose mapping using MOSFETs can take several days, and in this
study was completed over the course of 6 weeks to ensure a large enough charge
collection to ensure an adequate reading. In a clinical situation, this would not be
ideal. Instead, it would be preferred if the dosimetry could take place quickly, as a
means of quality assurance of planning, prior to administration to the patient.

4.4. FUTURE RESEARCH
The overall aim of this project is to produce a dose map of eye plaque brachytherapy
treatment, and verification of the spectroscopic dosimetry system. If such a dose
map can be produced for the sclera using a MOSFET based dosimeter, there is
potential to use other methods such as film to further map the dose, possibly at
depth within the eye. Before the film is used to gain understanding of the dose at
depth, a MOSkin may again be used to find the dose only a few microns below the
sclera.
Although the above results can contribute greatly to this final goal, further
measurements must be taken and improvements to the experimental method made.
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For example, the experimental setup did allow for a small amount of air to be
present between the MOSkin and the eye plaque.
A MOSkin is a precise and reliable piece of equipment when used in areas such as
this. However, it is still suggested that these same measurements be completed
multiple times to ensure that the initial and proceeding measurements are not
misleading or incorrect. Numerous measurements will also allow a dose map with
much less uncertainty to be created. Unfortunately, this was beyond practicality
during this research due to time constraints, and the limited lifetime of individual
MOSkin detectors used throughout.
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5. DEPTH DOSE USING GAFCHROMIC FILM
It is the aim of this research that the final product will be not just a scleral dose map,
but a dose map for eye plaque brachytherapy treatment and verification of the
spectroscopic dosimeter. Film is an excellent and recognised way to determine dose
in a phantom at depths, and so may be used to verify these results.
To complete an analysis of the dose at depths, two methods will be used. The first,
discussed in this chapter, is dosimetry with Gafchromic film. The second, is through
spectroscopic dosimetry, and will be discussed in Chapter 6.

5.1. METHODS
Using a different eye phantom to that which has been utilised in past chapters, along
with film, it is hoped to gain a better understanding of the dose from an eye plaque
at depth. The phantom which was used is a segmented acrylic eye and can have a
layer of film inserted between each 7mm segment. This can be seen in Figure 21.

Figure 21- Segmented Eye Phantom
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The film used for this dose calculation is EBT2 Gafchromic film, manufactured by
ISP Technologies Inc. The advantage of using EBT2 is that it is waterproof and
relatively light insensitive, allowing it to be worked with in the open without being
affected by ambient light. This film is also easily cut, allowing small squares to be
inserted into the phantom which can be worked with easily.
As seen in Figure 21, the segmented eye phantom is held together by a long screw. If
we were to continue to use this whilst using the film inserts, it would be impossible
to observe the dose in the centre of eye. As a result, paraffin wax was used to fill the
hole in each layer as it is near tissue equivalent.

5.1.1. CALIBRATION
In order to calibrate Gafchromic film, it is irradiated for varying times at a known
distance from a known source. The setup for the Film calibration was the same as
that used for the MOSFET calibration, with a single Oncura Thin Seed placed 1cm
away from the film in solid water, left over incremental time periods.
The colour change observed in Gafchromic film is in the red spectrum (due to the
incident dose), using blue channel correction. In order to calculate the dose, the film
is first split into the 3 colour channels. With this information, film was left over
multiple hours, 1cm from a single IsoAid I-125 brachytherapy seed. The results are
shown in Table 3.
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Table 3- Results from film calibration
Time taken for irradiation

Net OD

Known Dose (cGy)

24

0.00

5.74

48

0.03

11.28

72

0.05

16.52

144

0.07

22.75

192

0.08

28.22

(hours)

The dose in Table 3 was the expected dose calculated for each film calibration using
TG-43 guidelines. As the seed activity is known on the initial day of calibration, the
dose rate can be determined, and from this, the dose over the specified time
determined.
The optical density resulting from the colour change in the red channel observed in
the film for known doses can then be plotted, as demonstrated in Figure 22, where a
calibration factor of 277.6cGy/OD was obtained from the gradient of optical density
vs dose. The reason the red channel is used is that a dose range of 1cGy-10Gy can be
measured [3]. The differences between the colour channels are shown in Figure 23.
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Figure 22- Film calibration chart. Error in net OD derived from the standard deviation of the
measurements in ImageJ

Figure 23- The three colour channels of slice 6. The most distinct colour change can be seen
in the red channel

The colour change is shown in all results as the average pixel value in a circular ROI
of 50 pixel diameter to encompass as much of the irradiated area as possible, it is
possible to find the average pixel value of various colour channels. This analysis has
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the potential to produce a range from 0-255 with 0 being the closest shade to black
and 255 being closest to white.
The net optical density of the red channel is used to determine dose. It is found using
the following equation:

(14)

The gradient obtained from the calibration curve gives a relationship between
Optical Density and dose to the film, and is used to determine the dose to the
experimental films, as shown in the results.
The experiment was also completed a second time using only 7 seeds. In this case,
the only seeds used were those in the outer ring of the eye plaque. It was again left
for 72 hours and the activity of the seeds was recorded. Many combinations of seeds
are used in clinical practice, and it is important to note that these combinations
provide an observable dose difference.

5.2. RESULTS
The results obtained by leaving 7 sheets of film between the segments of the eye
plaque can be seen in Figure 24. Labels 1-7 represent the location of each slice of the
phantom with 1 at the base and 7 at the top of the phantom, as demonstrated in
Figure 25.
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Figure 24- 7 sheets of film from eye phantom after being left for 72 hours with a 15mm
ROPES eye plaque containing 10 seeds at 0.215mCi

Figure 25- Segmented eye phantom showing labelled film positions
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To obtain these results, the film was irradiated over a period of 72 hours with I-125
brachytherapy seeds of activity 0.215mCi. It was then left to develop a further 24
hours before being scanned using a ScanMaker i800 scanner in positive transmission
mode.
The results obtained using the described method are shown in Table 4. Using TG-43
based calculations, a comparison was made between the results from film and the
TG-43 analytical results shown in Figure 26.

Table 4- Maximum dose rate results from film irradiated for 72 hours with 10 seeds
of activity 0.215mCi in a ROPES eye plaque. The average pixel value was found
using a circular ROI of 50 pixel diameter in ImageJ
Film Slice

Depth (mm)

Average pixel
value

Net OD

Dose (cGy)

1

21.18

183.4

0.03763

1.492

2

18.40

180.8

0.04383

1.664

3

15.32

178.9

0.04842

1.791

4

11.97

161.5

0.09286

3.025

5

8.65

144.2

0.14206

4.390

6

4.99

114.7

0.24147

7.149

7

1.96

80.2

0.39686

11.461
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From the results in Table 4, it can be seen that the expected depth dose trend is
obtained. The results from both the film and TG-43 calculations, as shown in Figure
26, show a correlation, to within experimental error, where the errors estimated in

the figure include error in placement of the probe and the error of the measurement
of the dose with the probe. Although differences are evident, there are various
reasons this could occur, such as directional dependence, length of time and the use
of an acrylic phantom as opposed to water.
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Figure 26- Depth dose obtained using film and TG-43 calculations, using 10 seeds of
0.215mCi in a 15mm ROPES plaque for 72 hours of exposure

The results from reducing the number of seeds in the plaque are shown in Figure 27.
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Figure 27- 7 Sheets of film irradiated for 72 hours with 7 I-125 Brachytherapy seeds, placed
in the outer holder positions (4-10) of the 15mm ROPES plaque, using seeds with an activity
of 0.195mCi

The interpretation of the data obtained using only 7 seeds is more difficult than that
with 10. As seen in Figure 27, in slice 7, and further emphasised with the analysed
data in Figure 28 and Figure 29, the maximum dose at any given depth does not
necessarily fall along the central axis where the prescription dose point usually falls.

54

Central and Maximum Dose
8
7

Dose (cGy)

6
5

4

Maximum Dose

3

Central Dose

2
1
0
0

5

10

15

20

25

Depth (mm)

Figure 28- The central and maximum dose found using 7 seeds of activity 0.195mCi in a
15mm ROPES plaque for 72 hours of exposure, showing the difference between the two is
greater closer to the plaque.

Figure 29 profile across the centre of film from position number 7, using only 7 seeds.
Analysed by inverting the image, highlighting the difference in dose along the central axis
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5.3. DISCUSSION
The results in this section show that there is currently a difference in technique
between the dosimeters used for depth dose measurements in eye plaque
brachytherapy and the results obtained using analytical methods. This shows that
there is a need for a new method by which to set the standard for depth dose
measurements for eye plaque brachytherapy.
Other studies completed using film to investigate the dose using eye plaques have
shown that film works as a dosimeter, but have not compared these results to TG-43
analysis, nor completed an absolute dose calibration [50].
The results in this section show some differences between the analytical and
experimental results. This may be due to the differences in the density and atomic
number of an acrylic phantom as opposed to water. The results displayed were
taken over 72 hours, after which the scanning process was also lengthy. It can be
shown with these results, that if a faster and more accurate dosimetry modality
existed for the determination of depth dose with the use of eye plaques, it could be
more appropriate for implementation in clinical use.
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6. SPECTROSCOPIC DOSIMETRY
A small spectroscopic dosimeter has been developed at the Centre for Medical
Radiation Physics, University of Wollongong, which may measure dose rates to
point locations from low dose rate brachytherapy sources, suitable for eye plaque
brachytherapy dosimetry. The full dose map within an eye plaque treatment,
including scleral doses and dose measurements at depth, can be obtained with a
combination of MOSFET and spectroscopic dosimeter measurements.

Figure 30- Spectroscopic dosimeter developed at the CMRP Wollongong. The tip seen in
later figures is to the left, with the preamplifier on the right.

The spectroscopic dosimeter, as shown in Figure 30, was constructed using a small
silicon detector of size 1

, contained within a ceramic holder, directly couple to a

FET based amplification system, connected to a circuit board with preamplifier. The
probe was connected to a data acquisition unit, originally constructed to be used for
urethral dose measurements during low dose rate prostate brachytherapy. The data
acquisition unit contained a shaping amplifier, MCA/oscilloscope output and
onboard microprocessor for dose calculation and display. The microprocessor was
programmed to count the number of pulses from the shaping amplifier which were
above a set threshold, representing the lowest energy to consider when tallying
events in the detector. By setting the threshold just below the photopeaks from an I125 seed, the lower energy noise may be neglected, leaving the tally representing the
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integral of the counts in the photopeak region. As spectroscopic dosimetry assumes
the number of counts obtained in a fixed time frame is proportional to the dose rate
at the point of measurement, a calibration of the system allows the output of the
dose per hour (cGy/hr).
The MCA system was connected to a computer, allowing the observation of the raw
spectrum obtained by the detector as seen in Figure 31.
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Figure 31- Raw I-125 spectrum observed by the spectroscopic dosimeter. The sharp peak at
20 keV shows the discriminator pulse, below which, no integration is performed.

The display unit allows different timing options. 1, 3, 5 or 10 second acquisitions can
be used to determine the dose rate. It is expected that during measurement, the
longer the timing window, the more accurate the result. This was tested during data
taking, and it was found that the reading was more reproducible with a longer
timing window, with the average result of the shorter acquisition times being
approximately the same.
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The dose rate which is used in most calculations and results is taken directly from
the above unit. In the future, it is hoped that this technology can be used as a fast
and reliable way of calculating the dose which will be received by a patient
undergoing eye plaque brachytherapy. It will enable medical physicists to not only
determine the dose to the apex of the tumour, but also to the surrounding tissue.

6.1. METHODS
6.1.1. SENSITIVE VOLUME
The sensitive volume of the spectroscopic detector would ideally be situated at the
surface of the detector. However, as the detector used was a prototype, the sensitive
volume was situated several millimeters beyond the tip. In order to calculate this
distance, it was first measured using callipers. An x-ray of the detector showing the
location of the sensitive volume (Figure 32) was then obtained. The result was that in
the initial probe design, there was a space of 5.4mm between the tip of the probe and
the sensitive volume of the detector.
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Figure 32- X-ray of the original spectroscopic dosimeter design showing the tip of the
detector and sensitive volume, as well as the ceramic holder.

As the initial design of this detector was used in this research, the results presented
may be more accurate with later designs. The ceramic holders which can be seen in
the x-ray image may perturb the detected radiation. Future detector designs will
account for this and as a result, produce more accurate results.
This space between the sensitive volume and the tip of the detector makes it difficult
to get an accurate reading close to the surface and so is being further developed in
order to accomplish a smaller spacing. Another problem in this particular set up is
the ceramic holders, seen either side of the sensitive volume on the x-ray, which
attenuate some of the incoming photons. However, this particular detector setup is a
prototype, and will be altered to correct these issues.
After testing of the initial prototype, a second diode was fixed in the spectroscopic
probe. The resolution of various diodes was tested using the spectrum of I-125, and
the one with the highest resolution (smallest Full Width Half Maximum- FWHM)
was used. The ceramic holders were located behind the detector, not between the
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detector probe and tip, with the sensitive volume closer to the surface than the initial
design. An x-ray of this modified detector is shown in Figure 33.

Figure 33- X-ray image of the Modified spectroscopic detector, showing the sensitive
volume much closer to the tip (4mm).

Each new prototype must be evaluated in the same way as those mentioned above.
That is, with each new detector, an x-ray image, or similar, must be taken in order to
calculate the distance between the tip of the probe and the sensitive volume within.
The tip and volume spacing will change depending on the diode and its placement.

6.1.2. CALIBRATION
In order to calibrate the spectroscopic detector, the probe was placed in water at a
known depth from an I-125 based brachytherapy seed, according to TG-43
guidelines. In order to do this, the 5.4mm distance between the sensitive volume of
the diode and the tip of the probe is accounted for.
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The tip of the first detector was placed 4.6mm from a seed submerged in water, and
the dose per hour was calculated using a TG-43 based algorithm and found to be
0.22cGy/hr. Once this calibration was completed, the assumption was made that any
increase in dose would be linearly related to the number of counts, as such, the
calibration would hold for all other measurements.
For the calibration of the second detector, the same procedure was undertaken in
water using a single seed of known dose, with 1cm between the sensitive volume
and the seed, with the eye plaque placed 6mm from the tip of the detector. Another
component of the calibration of the detector is the setting of the energy threshold. As
mentioned previously, the unit is capable of sending a pulse out at the threshold
voltage, below which the counts observed are not considered and are instead
discarded before calculation. The energy at which this point is located can be altered
to ensure that the apparatus can be used for various sources, allowing observation of
as many different energy peaks as required. As a result, the lower energy threshold
discriminator must be calibrated to ensure that no useful data is being rejected,
whilst as many background and scattered counts as possible are deemed negligible
to ensure accurate data. The lower energy threshold was set to be at approximately
20 keV, just below the tail of the 22 keV fluorescent peak.

6.1.3. DOSE AT DEPTHS
Spectroscopic dosimetry remains a valuable, comparable tool to determine the dose
produced by a loaded eye plaque against other detector results. It is hoped that with
future development, and a mechanical system of movement, that the spectroscopic
detector will function as a fast and accessible method through which to determine
the dose a patient is to receive after implantation. To test the capability of the
spectroscopic dosimeter to be used as a quality assurance to for eye plaque
brachytherapy verification, a depth dose profile in a water phantom was obtained.
The setup used for this involved the lowering of the detector into water toward a
loaded eye plaque using a micrometer for precision, as depicted schematically in
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Figure 34, and photographed in Figure 35. Despite the mechanisms depth accuracy,
it is difficult to ensure that the tip of the probe and the centre of the eye plaque align.

Figure 34- Experimental setup of spectroscopic detector
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Figure 35 Photograph of the spectroscopic dosimeter apparatus

6.2. RESULTS
The exponential results shown in Figure 37 are of the same pattern expected of a
plaque over distance. From the data plotted, an exponential fit was applied, allowing
the dose rate to be calculated using the determined parameters, which are shown in
the following equation:

(15)
After the sensitive volume was removed and replaced with one located 4mm from
the tip of the probe, results requiring a shorter distance over which extrapolation
was required to determine the surface dose were found. These results agreed within
0.2cGy/hr with those found for position A using the MOSFET as described in the
previous chapter. These comparisons are explained in detail in Chapter 7.
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The spectroscopic detector results can be seen in Figure 36.

Depth Dose of I-125 ROPES brachytherapy Plaque using
seeds of activity 0.4mCi
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Figure 36- Measured Depth Dose of the spectroscopic Detector. The source activity was
normalised to 0.4mCi (Equation 12), a 10 second timer was used, and 3 to 4 outputs were
averaged to obtain the data. The results had an experimental error to within 1%

A close comparison of TG-43 values to the data obtained by the spectroscopic
detector can be seen in the above graph. The results show a discrepancy of
0.36cGy/hour, or 11.8% between the results at 5mm depth, and a difference of
0.05cGy/hr, or 13.8% at 23mm depth. These discrepancies are likely to be due to the
difficulties experienced in the positioning of the detector accurately above the
plaque. Later generations of the probe design will permit greater accuracy through
better localisation of the detector within the probe tip.
The dose rate at the scleral dose on the central image of the plaque using seeds of
0.4mCi, detected using a MOSFET was found to be 36.5cGy/hr with an error of
±0.5cGy/hr. From an extrapolation of the initial spectroscopic results, the dose rate
at position A was found to be 36.3cGy/hr, differing by only 0.6%.
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The steeper gradient of the spectroscopic data is likely caused by a discrepancy
between the distance to the sensitive volume assumed for calibration and the actual
distance from the plaque to the sensitive volume. Future generations of the design
will position the sensitive volume closer to the probe tip, allowing for more accurate
localisation of the detector within the eye plaques for both calibration and
measurement.

6.2.1.

DETECTOR FUNCTIONALITY

Until now, the fact that spectroscopic dosimetry is correctly interpreting the dose
rate has been assumed. To ensure that spectroscopic dosimetry is calculating the I125 dose rate correctly, spectra were obtained at varying tip to plaque depths. The
trends seen in these results show that the location of the I-125 spectral peaks (in
terms of channel) and shape are the same across all graphs. This is to be expected as
the number of counts or intensity at various channels should change with depth.
The spectral data was obtained using the same equipment as specified for the
calibration of the dosimeter. An MCA connected to the setup was the means of
obtaining the spectral data displayed below.

66

Spectra obatined at 1mm distance from tip to
ROPES plaque
1600
1400

Number of counts

1200
1000
800
600
400
200
0
4 6 7 8 10 11 12 14 15 16 18 19 20 22 23 24 26 27 28 30 31 32 33 34 35
Energy (keV)

Figure 37 Spectra obtained using a spectroscopic dosimeter and fully loaded I-125 ROPES eye plaque
with a tip to plaque distance of 1mm
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Figure 38 Spectra obtained using a spectroscopic dosimeter and fully loaded I-125 ROPES
eye plaque with a tip to plaque distance of 2mm
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Spectra obatined at 3mm distance from ROPES
plaque
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Figure 39 Spectra obtained using a spectroscopic dosimeter and fully loaded I-125 ROPES
eye plaque with a tip to plaque distance of 3mm

Spectra obatined at 5mm distance from ROPES
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Figure 40 Spectra obtained using a spectroscopic dosimeter and fully loaded I-125 ROPES
eye plaque with a tip to plaque distance of 5mm
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Spectra obatined at 10mm distance from ROPES
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Figure 41 Spectra obtained using a spectroscopic dosimeter and fully loaded I-125 ROPES
eye plaque with a tip to plaque distance of 10mm

It can be seen in the above figures (Figure 37-Figure 41) that there is a trend
emerging with the spectra. The peaks of the spectra align at the same channel
numbers (energy), and although the intensities differ, there are still similarities in the
shape. That is, the first peak, occurring at 22 keV is proportionally smaller than the
27 keV peak. These recurring trends indicate that the concept of spectroscopic
dosimetry may be applied, as the peak heights are not varying relative to each other
by more than 8%, where the photopeaks are assumed to have the same or similar
attenuation rates in the water medium.
The full width half maximum (FWHM) of the 22keV and 27keV peaks are shown in
Table 5. As per above, the intensity of the peaks is reliant on the depth. However, the
FWHMs show that despite the variations in the depth of measurement, the peaks
maintain a constant FWHM. Therefore, regardless of depth, the relative distribution
of energy across the peaks does not change, indicating that the data obtained by the
spectroscopic dosimeter should not be affected by depth.

69

Table 5- FWHM comparison of peaks obtained at varying depths using an I-125
source
Distance

FWHM 22keV peak

FWHM 27keV peak

1mm

57

51

2mm

61

47

3mm

62

49

5mm

61

47

10mm

61

54

Average

60.4

49.6

An analysis of this data shows that the variation of the FWHM for any given peak
deviates from the average no more than 5% for the 22keV peak, and no more than
8% for the 27keV peak. Using more a more comprehensive set of measurements,
including multiple takes and an analysis of probe angle, these errors would not be as
large, and would further prove that there is little to no discrepancy in the
spectroscopic dosimeters ability to effectively measure dose at varying depths. Such
work is beyond the scope of this thesis due to time constraints, but may be further
developed in future.
The linearity of the probe was not tested, but was assumed to be adequate as the
count rates throughout the experiment were very low, and as such, multiple events
are rarely occurring within a short space of time, causing very little pile-up effects.
This was proved somewhat by multiple readings at each measurement point
showing little fluctuation.
Table 6 shows the ratio of the sum of all counts under the spectra (energies 1435keV) to the dose rate at the given depth. In this case, the time taken to obtain each
spectra was also accounted for, as this has a large effect on the ratio. The resulting
factors vary by only about 5%, which can be accounted for by the errors discussed in
the following section.
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Table 6- Ratio of counts obtained in each spectra and the dose rate at specified
depth
Depth (mm)

Sum of

Time (s)

counts

Dose Rate

Sum/Time/Dose

(cGy/hr)

Rate

1

168186

132

7.52

169

2

162601

156

5.97

175

3

118090

145

4.7

173

5

96951

189

3.04

169

10

50565

227

1.22

183

The similarities of these ratios express the validity of the ability of the spectroscopic
dosimeter to accurately measure dose at depths. As with the comparison of the
FWHM, this result accounts for the variable factors within the results (the time taken
to obtain the spectra and the dose rate at varying depths) to ensure that the results
show the constancy of the I-125 spectra, regardless of these factors.

6.3. DISCUSSION
The depth dose results from the spectroscopic dosimeter in closer agreement with
the analytical, TG-43 results than the traditional dosimeter, film due to the
differences in phantom medium. It was shown in this section of research that the
spectroscopic dosimeter is also faster in obtaining results, an advantage if it were to
be implemented clinically.
The speed of the spectroscopic dosimeter makes it an ideal candidate for clinical
treatment planning quality assurance. It is believed that the detector could be used
prior to treatment using eye plaques, to ensure the dose rate at various depths will

71

be as planned, when the potential for positional errors has been eliminated from the
design.
In terms of reproducibility, the average standard deviation contained in the
spectroscopic detector was less than that observed when using the film. This also
gives precedence to the introduction of such a device clinically, as calibration can be
completed before use, and once calibrated, the device returns consistent results.
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7. CONCLUSION
The three major aims that were achieved and documented throughout this research
include:
i. The production of a scleral dose map using a MOSFET based detector (MOSkin) to
provide information as to the areas of the sclera that are at the greatest risk of
necrosis or other adverse effects. These results were comparable to those
extrapolated from the spectroscopic dosimetry results and TG43 based calculations.
ii. The development of a method by which eye plaque dosimetry can be performed
quickly and with ease, potentially before treatment begins, which will progress
further with updated versions of the spectroscopic dosimeter.
iii. The feasibility of novel solid state dosimetry was tested, by studying the results
obtained through MOSFET and spectroscopic dosimetry, comparing these to more
conventional TG-43 and film results.
The first component of this research showed that a scleral dose map can be
completed using MOSFETs. It also indicates that by using current dosimetric
modalities, detailed dosimetric information cannot be replicated in a fast and
accurate manner.
Producing depth dose results using film reveals the need for a real time dosimeter,
capable of both surface and depth doses. It is hoped that in the future, the
spectroscopic dosimeter used in this research may be applied, and eventually
implemented clinically.
In this research, the spectroscopic detector developed by the CMRP gives results that
show the potential for use as a fast quality assurance tool for eye plaque
brachytherapy, and were comparable with other detectors and analytical results
obtained using TG-43 protocols. This has a large number of practical implications for
both treatment centres and future research as discussed at length in Chapter 1.
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The results obtained by the spectroscopic detector agreed with results obtained by
the film used for depth dose, within expectation. MOSFETs used for surface dose
through extrapolation and the values calculated using the TG-43 formalism, when
positional errors are considered. Discrepancies in the spectroscopic dosimetry
measurements may be due to a small offset in the calibration and/or measurement
location, which will be addressed in a future probe version, which is being designed
to have the sensitive volume of the detector as close to the tip of the probe as
possible.
A comparison of the dose measurements taken with the film and those obtained by
TG-43 calculations show correlation between the two dosimetry methods. However,
the results comparing the analytical results and those obtained by the spectroscopic
dosimeter are excellent. This gives evidence for spectroscopic dosimetry being as
accurate as Gafchromic film when determining dose at depths. This also helps
validate that the TG-43 calculations are accurate and can be used to evaluate other
dosimetry methods.
To further ensure the accuracy of the spectroscopic probe, the results showing the
scleral dose map taken using MOSFETs was compared to an extrapolated dose
obtained by the spectroscopic probe. These results agree well with one another and
show the accuracy of both the spectroscopic probe and MOSFETs alike. Positional
errors within the calibration of the spectroscopic dosimeter are more noticeable at
greater depths.
It can be concluded from the agreement and accuracy of the obtained data that in
future, the spectroscopic probe developed by the CMRP will have a strong clinical
impact with future iterations of the design. With the improved accuracy promised
with evolving designs, it is thought that in future, treatment centres administering
eye plaque brachytherapy treatment will be able to use such a detector to ensure
accurate and reliable treatment to all patients.
From the results seen thus far of the spectroscopic detector, it is also possible that in
future it will have applications beyond that of eye plaque brachytherapy. These
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applications may include other forms of brachytherapy, such as LDR prostate
brachytherapy, and may be applied to a wide variety of radioisotopes.

7.1. FUTURE APPLICATIONS
Improved positional accuracy will be possible with future generations of the
spectroscopic detector. The setup shown and described can be improved in further
iterations to ensure no deviations from the central axis occur as the detector is
moved through the various depths of the water phantom. This will also allow
greater control in the horizontal plane and as such, use for comprehensive dose
mapping.
In a new design probe currently under development at CMRP, the sensitive volume
of the detector will be moved closer to the tip, with no ceramic components housing
the detector, allowing more accurate results to be obtained closer to the surface of
the eye, possibly giving a faster, more accurate method of dose mapping. The
ceramic holders will be moved so as not to perturb the incoming radiation, and the
setup through which the measurements are taken will account for potential
positional errors. As a result, the data obtained by the detector will be more accurate
with future developments.
In clinical applications, it is expected that the spectroscopic detector will be further
developed to allow dose mapping for eye plaque brachytherapy prior to treatment.
This will result in a readily available quality assurance modality, which will help to
ensure correct dose to patients as well as a method by which to ensure the planning
system output is being correctly implemented in treatment.
In future, a spectroscopic dosimeter such as the spectroscopic probe may be used to
quickly and accurately assess the dose rate from eye plaque brachytherapy, and
therefore the total dose distribution to the eye and surrounding areas can be
determined. This will allow a much greater accuracy in the planning and
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administering of treatment and with the correct use, it is hoped that this may result
in less enucleations and a greater rate of remission in all ocular malignancies.
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9. APPENDIX 1
Adapted from [52]

Authors

Radiation
Source

Mean apex
dose (Gy)

Recurrence Enucleation
(%)
(%)

Metastasis
(%)

Visual acuity

Packer et
al.

125I

results

91

7.8

17.2

15.6

45% better or 20/100

Fontanes
i et al.

125I

results

79

2.3

9.7

5.5

41% better or 20/200

Giblin

125I

results

97

7.2

8.8

6.1

47% better or 20/200

Kreissig
et al.

125I

results

70

10

0

15.7

100%
“severe loss of vision”

Melia et
al.

125I

results

Variable*

NA

NA

NA

57% better than 20/200

80.5

4

6

6

73% better than 20/200

100

15

26

20

NA

Finger

103Pd

results
Lommat
zsch

106Ru

results
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